Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: purging efficacy, hematopoietic reconstitution in non-Hodgkin's lymphoma (NHL): results of Japanese phase II study

Abstract

Summary:The purging efficacy of positive selection of autologous CD34þ PBSC with a clinical scale method of magneticactivated cell sorting system (CliniMACS) was investigated in 48 patients with non-Hodgkin's lymphoma (NHL). The median purity and recovery rate of the CD34 þ cells postselection were 93.3% (range 32.6-99.3) and 72.2% (range 20.5-309.8), respectively. The real-time PCR method to detect the patient-specific monoclonal immunoglobulin heavy chain gene rearrangement (minimal residual tumor; MRT) and CD19 and CD20 positivities were used for the detection of contaminating NHL cells before and after CD34 þ selection. After selection, the median (range) depletion rate of MRT was 2.53 (1.52-4.78) log, and that of CD19 þ cell and CD20 þ cell was 2.46 (0.74-3.64) log and 2.32 (0.40-4.01) log, respectively. In 41 patients, high-dose chemotherapy was performed, followed by the transplantation of the isolated CD34 þ cells. Rapid neutrophil recovery as well as platelet recovery was seen with a median time to reach 0.5 Â 10 9 /l neutrophils of 10 days (range 8-13) and 20 Â 10 9 /l platelets of 14 days (range 10-34), respectively. The present study demonstrated that CliniMACS is a highly effective positive selection method and a high purging efficacy could be obtained without compromising the hematopoietic reconstitution capacity of the graft in NHL patients undergoing high-dose chemotherapy.

Virus reactivation in high-risk non-Hodgkin’s lymphoma patients after autologous CD34+-selected peripheral blood progenitor cell transplantation

“…In our study, the data of recovery and purity rates, the engraftment time of neutrophils and platelets and the depletion log of CD3 + and CD19 + are similar to those previously reported [19][20][21]. Autologous CD34 + -selected PBPC transplantation using CliniMACS showed high efficacy without compromising the hematopoietic reconstitution capacity of the graft.…”

Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study

“…G-CSF was used for mobilization of peripheral blood progenitor cells after the hyper-CVAD/MA protocol during bone marrow recovery. High-dose chemotherapy before ASCT included one of three regimens: ICE (ifomide, carboplatin, etoposide), MCEC (ranimustine, carboplatin, etoposide, cyclophosphamide), or MEAM (ranimustine, cytarabine, etoposide, melphalan) (Wilson et al 1992 ; Imai et al 2005 ; Abrey et al 2003 ; Takasaki et al 2013 ).…”

Stem cell separation from cord blood

“…Positive selection, by labeling the target cells, is the fastest and the most efficient way to isolate a cell subset with high purity and Stem cell separation from cord blood @ C I C E d i z i o n i I n t e r n a z i o n a l i yield, but because separation is based on a single parameter (i.e., magnetization), this method is generally effective only for the isolation of a single cell population. Moreover, the purity of the recovered yield was variable in different studies (11,12), but some Authors suggested that the magnetic separator performance in terms of purity and recovery is either comparable with or superior to other technologies (13). Others reported that isolation of stem cells from blood or bone marrow by MACS was a powerful technology for manipulation of the hematopoietic system (14).…”